Table. 1 Subject-, disease- and transplant-related variables.

Number	Age	Sex	Underlying disease	Conditioning	GvHD prevention	Graft source	CD34 × 10E + 6/kg	D–R ABO mismatch	Prior therapy	Dose/w (mg)	Best response	Disease state	Survivals
1	60	M	MDS	Flu /TBI	CSA/MMF	PBSC	4.4	No	SDP, IGIV, G-CSF	350	NoR	CR	Dead
2	34	M	AA	CY/ATG	CSA/MTX	PBSC	2.75	No	SDP, IGIV, G-CSF	350	CR	CR	Alive
3	47	M	MDS	Bu/CY/ATG	TAC/MMF	PBSC	6	No	SDP, IGIV, G-CSF	700	NoR	CR	Alive
4	48	F	AML	Flu/CY/TBI	CSA/MMF/PTCY	PBSC	4.2	No	SDP,IVIG, G-CSF	700	NoR	CR	Dead
5	43	F	HL	Flu/Bu	CSA/MMF	PBSC	4.76	Yes	SDP, IGIV	525	CR	CR	Dead
6	8	M	AA	Flu/CY/TBI/ATG/PTCY	TAC/MMF/PTCY	BM	9.19	Yes	SDP, IGIV,G-CSF	700	NoR	CR	Alive
7	47	F	AML	Flu/CY/TBI/PTCY	CSA/MMF	PBSC	6.56	No	SDP, G-CSF	350	NoR	CR	Dead
8	49	F	ALL	BuCY/TBI/PTCY	TAC/MMF/PTCY	BM	4.32	Yes	SDP	700	CR	CR	Alive
9	28	M	HL	Flu/CY/TBI	CSA/MMF	PBSC	6.2	No	SDP	350	CR	NCR	Dead
10	45	F	AML	Bu/CY	CSA/MTX	PBSC	6.45	Yes	SDP, IGIV, G-CSF	450	CR	CR	Alive
11	61	F	PMF	TBF	TAC/MTX	PBSC	8.88	Yes	SDP, IGIV, G-CSF	525	CR	CR	Alive
12	26	M	DC	Flu/CY/TBI/ATG	TAC/MMF	BM	4.58	Yes	SDP, IGIV	350	CR	CR	Alive
13	26	F	FA/MDS	Flu/CY/TBI/ATG	TAC/MMF	BM	2.63	No	SDP, IGIV	625	CR	CR	Alive
14	37	M	HL	Flu/CY/TBI/PTCY	CSA/MMF/PTCY	PBSC	9.48	No	IGIV	700	NoR	CR	Alive

PGF poor graft function, MDS myelodysplastic syndrome, AA aplastic anaemia, AML acute myeloid leukemia, HL Hodgkin lymphoma, ALL acute lymphoblastic leukemia, PMF primary myelofibrosis, FA Fanconi anaemia, DC Deskeratosis congenita, Flu fludarabine, TB total body irradiation, CY cyclophosphamide, ATG anti-thymocyte globulin, BU busulfan, PTCY posttransplant cyclophosphamide, T thiotepa, CSA cyclosporine, MM mycophenolate mofetil, BCT blood cells transplant, BM bone marrow, BMT bone marrow transplant, D–R ABO mismatch donor–recipient ABO mismatch, SDP single-donor platelet, IVIG intravenous immunoglobulin, G-CSF granulocyte colony-stimulating factor, CR complete response, NR no response.

Quick links

Search